Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) EBIT Margin (2022 - 2025)

Oramed Pharmaceuticals' EBIT Margin history spans 4 years, with the latest figure at 225.0% for Q1 2025.

  • For Q1 2025, EBIT Margin fell 72534.0% year-over-year to 225.0%; the TTM value through Dec 2025 reached 779.4%, changed N/A, while the annual FY2025 figure was 790.9%, 39899.0% up from the prior year.
  • EBIT Margin reached 225.0% in Q1 2025 per ORMP's latest filing, down from 1201.15% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 1201.15% in Q2 2024 to a low of 1693.92% in Q2 2022.
  • Average EBIT Margin over 4 years is 646.18%, with a median of 781.98% recorded in 2023.
  • Peak YoY movement for EBIT Margin: soared 176361bps in 2024, then tumbled -72534bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 1363.5% in 2022, then surged by 59bps to 562.46% in 2023, then soared by 314bps to 1201.15% in 2024, then plummeted by -119bps to 225.0% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBIT Margin are 225.0% (Q1 2025), 1201.15% (Q2 2024), and 500.34% (Q1 2024).